Search

Jeffery D Molkentin

from Cincinnati, OH
Age ~57
Get Report
Also known as:
Jeffrey D Molkentin, Jeff Molkentin, Jeffery D Molketin
Phone and address:
5756 Babygold Ct, Cincinnati, OH 45247
Related to:
Megan MolkentinDenise Kujawa, 60Linda Petersen, 61Mick Molkentin, 58
Connected to:
Britney Molkentin, 33Vickie L Molkentine, 74Alex F Moll, 55Ana T Moll, 79Annie H Moll, 110Brad A Moll, 63Brice M Moll, 37Cameron L Moll, 32Cecile F Moll, 62Charlene M Moll, 71

Jeffery Molkentin Phones & Addresses

  • 5756 Babygold Ct, Cincinnati, OH 45247
  • 1037 Thunderbird Ave, Cincinnati, OH 45231
  • Dallas, TX
  • Milwaukee, WI
  • Houston, TX
  • Hamilton, OH

Publications

Us Patents

Non-Immunosuppressive Cyclosporin For The Treatment Of Muscular Dystrophy

View page
US Patent:
20100323972, Dec 23, 2010
Filed:
Feb 5, 2009
Appl. No.:
12/866844
Inventors:
Jeffery D. Molkentin - Cincinnati OH, US
International Classification:
A61K 38/12
C07K 7/64
A61P 21/00
US Classification:
514 205, 530321
Abstract:
The present invention relates to the use of a non-immunosuppressive cyclosporin A derivative for preventing or reducing muscular degeneration in a subject suffering from Limb-Girdle muscular Dystrophy.

Regulation Of Cardiac Contractility And Heart Failure Propensity

View page
US Patent:
20110003844, Jan 6, 2011
Filed:
Apr 30, 2010
Appl. No.:
12/772024
Inventors:
Jeffery Daniel MOLKENTIN - Cincinnati OH, US
Evangelia Galani Kranias - Cincinnati OH, US
Assignee:
Children's Hospital Medical Center - Cincinnati OH
University of Cincinnati - Cincinnati OH
International Classification:
A61K 31/437
A61K 31/407
A61K 31/404
A61P 9/00
US Classification:
514294, 514410, 514414
Abstract:
The methods and compositions of the present invention find use in altering expression of PKCα in transgenic animals. The compositions of the invention include isolated transgenic animal cells, transgenic tissue, transgenic animals, and transgenic mice. The transgenic animals of the invention exhibit altered PKCα activity. The methods allow generation of transgenic animals with altered expression of PKCα. The invention allows modulation of cardiac contractility. In particular, the invention provides a method for altering the susceptibility of a transgenic animal to cardiomyopathy. A transgenic animal of the invention finds use in identifying anti-cardiomyopathic compounds.

Regulation Of Cardiac Contractility And Heart Failure Propensity

View page
US Patent:
20050066381, Mar 24, 2005
Filed:
Sep 17, 2004
Appl. No.:
10/944375
Inventors:
Jeffery Molkentin - Cincinnati OH, US
Evangelia Kranias - Cincinnati OH, US
Assignee:
Children's Hospital Medical Center - Cincinnati OH
University of Cincinnati - Cincinnati OH
International Classification:
A01K067/027
US Classification:
800018000
Abstract:
The methods and compositions of the present invention find use in altering expression of PKCα in transgenic animals. The compositions of the invention include isolated transgenic animal cells, transgenic tissue, transgenic animals, and transgenic mice. The transgenic animals of the invention exhibit altered PKCα activity. The methods allow generation of transgenic animals with altered expression of PKCα. The invention allows modulation of cardiac contractility. In particular, the invention provides a method for altering the susceptibility of a transgenic animal to cardiomyopathy. A transgenic animal of the invention finds use in identifying anti-cardiomyopathic compounds.
Control profile
Jeffery D Molkentin from Cincinnati, OH, age ~57 Get Report